C4 Therapeutics (CCCC) Liabilities and Shareholders Equity (2019 - 2025)
Historic Liabilities and Shareholders Equity for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $265.5 million.
- C4 Therapeutics' Liabilities and Shareholders Equity fell 2940.28% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 1963.7%. This contributed to the annual value of $349.6 million for FY2024, which is 713.21% down from last year.
- According to the latest figures from Q3 2025, C4 Therapeutics' Liabilities and Shareholders Equity is $265.5 million, which was down 2940.28% from $296.5 million recorded in Q2 2025.
- C4 Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $528.4 million during Q2 2021, with a 5-year trough of $265.5 million in Q3 2025.
- In the last 5 years, C4 Therapeutics' Liabilities and Shareholders Equity had a median value of $381.1 million in 2024 and averaged $404.4 million.
- Per our database at Business Quant, C4 Therapeutics' Liabilities and Shareholders Equity surged by 12167.23% in 2021 and then tumbled by 2940.28% in 2025.
- C4 Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $506.8 million in 2021, then fell by 14.98% to $430.8 million in 2022, then dropped by 12.62% to $376.5 million in 2023, then decreased by 7.13% to $349.6 million in 2024, then dropped by 24.06% to $265.5 million in 2025.
- Its Liabilities and Shareholders Equity stands at $265.5 million for Q3 2025, versus $296.5 million for Q2 2025 and $319.5 million for Q1 2025.